Bhardwaj Priya, Bekeny Jenna C, Zolper Elizabeth G, Nigam Manas, Sher Sarah R
Department of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, D.C.
Plast Reconstr Surg Glob Open. 2020 Aug 14;8(8):e2945. doi: 10.1097/GOX.0000000000002945. eCollection 2020 Aug.
Chlorhexidine is a topical antiseptic that is generally well tolerated in patients, making it a common preparatory substance in various surgical settings. Sparse case reports have identified immediate hypersensitivity reactions after exposure to this substance, especially in patients with a history of atopy. The purpose of this case report is to describe 3 unique presentations of delayed hypersensitivity to epidermal chlorhexidine preparation. Patients undergoing breast surgery by a single surgeon between December 2018 and January 2019 were retrospectively reviewed for incidence of dermatologic complications. Medical and surgical history of patients as well as dermatologic hypersensitivity course were collected. Three patients presented with a delayed hypersensitivity to the epidermal chlorhexidine surgical preparation, ChloraPrep. Each patient developed an erythematous, pruritic maculopapular rash in the distribution of the chlorhexidine application. This occurred beyond the immediate postoperative period-ranging from postoperative days 5 to 35. Initial treatment included the use of 1% hydrocortisone along with a systemic antihistamine. If there was no improvement in symptoms after 3 days, we transitioned patients to 0.5% triamcinolone ointment. If there was no improvement after 5 days on triamcinolone, the patient was reexamined and systemic steroids were prescribed. In each of our cases, all skin changes had resolved within 7-10 days of initial symptoms. Our findings highlight a series of delayed adverse reactions to epidermal chlorhexidine occurring beyond the intraoperative and immediate postoperative period. This case report serves to recognize a unique presentation pattern to ensure that all patients are accurately diagnosed and promptly treated via a systematic treatment algorithm.
洗必泰是一种局部抗菌剂,患者通常对其耐受性良好,这使其成为各种手术环境中常用的术前准备药物。少数病例报告指出,接触该物质后会出现即刻过敏反应,尤其是有特应性病史的患者。本病例报告的目的是描述3例对表皮洗必泰制剂迟发型过敏反应的独特表现。对2018年12月至2019年1月间由同一外科医生进行乳房手术的患者进行回顾性研究,以确定皮肤并发症的发生率。收集患者的内科和外科病史以及皮肤过敏病程。3例患者对表皮洗必泰手术制剂ChloraPrep出现迟发型过敏反应。每位患者在洗必泰涂抹部位出现红斑、瘙痒性斑丘疹。这种情况发生在术后即刻之后,时间范围从术后第5天至第35天。初始治疗包括使用1%氢化可的松以及全身性抗组胺药。如果3天后症状没有改善,我们将患者改用0.5%曲安奈德软膏。如果使用曲安奈德5天后仍无改善,则对患者进行复查并开具全身性类固醇药物。在我们的每一个病例中,所有皮肤变化在初始症状出现后的7 - 10天内均已消退。我们的研究结果突出了一系列发生在术中及术后即刻之后的对表皮洗必泰的迟发性不良反应。本病例报告旨在识别一种独特的表现模式,以确保所有患者都能通过系统的治疗方案得到准确诊断和及时治疗。